应用于非小细胞肺癌的表皮生长因子受体酪氨酸激酶抑制药个体差异性指标的研究现状  

Research status of individual difference parameters of epidermal growth factor receptor tyrosine kinase inhibitor applied to non-small cell lung cancer

作　　者：王紫愉 杜欣 吴紫阳 于之恒 杨丽[1] 刘维[1] 陈丁丁 WANG Zi-yu;DU Xin;WU Zi-yang;YU Zhi-heng;YANG Li;LIU Wei;CHEN Ding-ding(Department of Pharmacy,Peking University Third Hospital,Beijing 100191,China;School of Basic Medical Sciences and Clinical Pharmacy,China Pharmaceutical University,Nanjing 211198,Jiangsu Province,China;Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Sciences,Peking University Health Science Center,Beijing 100191,China)

机构地区：[1]北京大学第三医院药剂科,北京100191 [2]中国药科大学基础医学与临床药学学院临床药学系,江苏南京211198 [3]北京大学药学院药事管理与临床药学系,北京100191

出　　处：《中国临床药理学杂志》2021年第3期329-332,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家科技重大专项基金资助项目(2017ZX09304012006,2017ZX09304012007)。

摘　　要：表皮生长因子受体酪氨酸激酶抑制药(EGFR-TKIs)是治疗表皮生长因子受体突变的晚期非小细胞肺癌(NSCLC)的一线用药,在临床应用过程中,可观察到血药浓度及安全性、有效性的个体差异,可能与药物代谢酶和转运体的基因多态性相关。因此,本文对临床常用的6种EGFR-TKIs可能相关的药物遗传学指标和药代动力学指标进行整理并作一综述。Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) were recognized as the first-line drug for advanced non-small cell lung cancer(NSCLC) with epidermal growth factor receptor mutation worldwide. However, individual differences in blood concentration, safety and efficacy have been observed during clinical practice. The differences may be related to gene polymorphism of drug metabolizing enzymes and transporters. Therefore, this paper sorts out and reviews the pharmacogenetic and pharmacokinetic parameters of six EGFR-TKIs.

关 键 词：表皮生长因子受体酪氨酸激酶抑制药 非小细胞肺癌 药物遗传学 药代动力学 个体差异 

分 类 号：R979.1[医药卫生—药品]